- Home
- PCSA vs UOKA Comparison
PCSA vs UOKA Comparison
Compare PCSA & UOKA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCSA
- UOKA
- Stock Information
- Founded
- PCSA 2011
- UOKA 2002
- Country
- PCSA United States
- UOKA United Kingdom
- Employees
- PCSA 13
- UOKA N/A
- Industry
- PCSA Biotechnology: Pharmaceutical Preparations
- UOKA
- Sector
- PCSA Health Care
- UOKA
- Exchange
- PCSA Nasdaq
- UOKA NYSE
- Market Cap
- PCSA 3.3M
- UOKA 2.7M
- IPO Year
- PCSA N/A
- UOKA N/A
- Fundamental
- Price
- PCSA $0.22
- UOKA $2.40
- Analyst Decision
- PCSA Strong Buy
- UOKA
- Analyst Count
- PCSA 1
- UOKA 0
- Target Price
- PCSA $6.00
- UOKA N/A
- AVG Volume (30 Days)
- PCSA 46.5M
- UOKA 128.0K
- Earning Date
- PCSA 08-12-2025
- UOKA 08-16-2025
- Dividend Yield
- PCSA N/A
- UOKA N/A
- EPS Growth
- PCSA N/A
- UOKA N/A
- EPS
- PCSA N/A
- UOKA N/A
- Revenue
- PCSA N/A
- UOKA $48,375.00
- Revenue This Year
- PCSA N/A
- UOKA N/A
- Revenue Next Year
- PCSA N/A
- UOKA N/A
- P/E Ratio
- PCSA N/A
- UOKA N/A
- Revenue Growth
- PCSA N/A
- UOKA N/A
- 52 Week Low
- PCSA $0.15
- UOKA $1.98
- 52 Week High
- PCSA $3.10
- UOKA $42.50
- Technical
- Relative Strength Index (RSI)
- PCSA 44.28
- UOKA N/A
- Support Level
- PCSA $0.20
- UOKA N/A
- Resistance Level
- PCSA $0.33
- UOKA N/A
- Average True Range (ATR)
- PCSA 0.09
- UOKA 0.00
- MACD
- PCSA -0.01
- UOKA 0.00
- Stochastic Oscillator
- PCSA 6.53
- UOKA 0.00
About PCSA Processa Pharmaceuticals Inc.
Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on utilizing its regulatory science approach in the development of Next Generation Chemotherapy (NGC) oncology drug products. The company's strategic prioritization is to advance its pipeline of NGC proprietary small-molecule oncology drugs. The NGC products are new chemical entities, but the company works by changing the metabolism, distribution, and/or elimination of already FDA-approved cancer drugs or their active metabolites while maintaining the mechanism of how the drug kills cancer cells. The three NGC treatments in its pipeline are PCS6422 (also referred to as NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem), and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri).
About UOKA MDJM LTD
MDJM Ltd is engaged in providing real estate agency services to its real estate developer clients, and provides, on an as-needed basis, real estate consulting services and independent training services. The company generates all of its revenue from Hotel income. The company derives a majority of its revenue from the United Kingdom.